Health Care • Biotechnology: Pharmaceutical Preparations
$3.82 ▼ -0.06
(-1.55%)
MKT CAP: $267.4M • VOL: 598.2K
52W L $3 52W H $8
BCYC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $72.6M | $35.3M | $27.0M |
| YoY Revenue Growth % | +105.8% | +30.8% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$247.1M | -$209.9M | -$189.9M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$219.0M | -$169.0M | -$180.7M |
| EBITDA (Normalized) | -$245.2M | -$208.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$249.7M | -$164.7M | -$60.6M |
| Capital Expenditures (CapEx) | $2.4M | $1.2M | — |
| Free Cash Flow (FCF) | -$252.0M | -$166.0M | -$60.6M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $628.1M | $879.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $610.0M | $793.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BCYC.